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ABSTRACT
We aimed to develop evidence-based multinational
recommendations for the diagnosis and management of
gout. Using a formal voting process, a panel of 78
international rheumatologists developed 10 key clinical
questions pertinent to the diagnosis and management of
gout. Each question was investigated with a systematic
literature review. Medline, Embase, Cochrane CENTRAL
and abstracts from 2010–2011 European League Against
Rheumatism and American College of Rheumatology
meetings were searched in each review. Relevant studies
were independently reviewed by two individuals for data
extraction and synthesis and risk of bias assessment.
Using this evidence, rheumatologists from 14 countries
(Europe, South America and Australasia) developed
national recommendations. After rounds of discussion
and voting, multinational recommendations were
formulated. Each recommendation was graded according
to the level of evidence. Agreement and potential impact
on clinical practice were assessed. Combining evidence
and clinical expertise, 10 recommendations were
produced. One recommendation referred to the diagnosis
of gout, two referred to cardiovascular and renal
comorbidities, six focused on different aspects of the
management of gout (including drug treatment and
monitoring), and the last recommendation referred to the
management of asymptomatic hyperuricaemia. The level
of agreement with the recommendations ranged from 8.1
to 9.2 (mean 8.7) on a 1–10 scale, with 10 representing
full agreement. Ten recommendations on the diagnosis
and management of gout were established. They are
evidence-based and supported by a large panel of
rheumatologists from 14 countries, enhancing their utility
in clinical practice.
INTRODUCTION
Gout is one of the most common inﬂammatory arth-
ritis conditions, affecting up to 1–2% of men in
Western countries1 and causing morbidity, disability
and poorer quality of life.2 It is the consequence of
deposition of monosodium urate (MSU) crystals in
joints and other tissues, as a result of persistent
hyperuricaemia. The aim of treatment is to reduce
serum uric acid (SUA) levels, allowing MSU crystals
to dissolve, leading to the elimination of acute epi-
sodes of inﬂammation, the disappearance of tophi,
and, eventually, cure of the disease.3 However, sub-
optimal management of the condition is still
reported4–6 despite the publication of a number of
guidelines and recommendations,7–11 the develop-
ment of new therapeutic agents, and the introduc-
tion of target-directed management strategies.12
Some evidence suggests that guidelines that are
implemented improve quality of care and that inter-
ventions involving educational outreach may help
the successful implementation and dissemination of
guidelines.13
The 3e (Evidence, Expertise, Exchange) Initiative
is a unique multinational collaboration aimed at
promoting evidence-based practice in rheumatology
by developing practical recommendations addres-
sing relevant clinical problems.14–16 Unlike most
existing guidelines or recommendations developed
by a limited panel of experts in the ﬁeld, the 3e
Initiative involves a large number of practising
rheumatologists from around the world.
Recommendations are made in response to the
identiﬁcation of the 10 most important clinical
questions posed by the group, rather than the more
all-purpose method of generating treatment recom-
mendations. The objective was to develop evidence-
based and practical recommendations for the
diagnosis and management of gout with consensus
from a large number of practising rheumatologists
from many countries. In addition, through the dis-
semination of the results of systematic literature
reviews (SLRs) to such a large number of rheuma-
tologists, an understanding of the current extent of
knowledge in this ﬁeld was widely shared. This edu-
cational activity may increase the uptake of the
guidelines.
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METHODS
A total of 474 rheumatologists from 14 countries participated in
the 2011 3e Initiative. Twelve scientiﬁc committees represented
participating countries from Europe, South America and
Australasia. The members of each of the national scientiﬁc com-
mittees formed a panel of experts who attended the multi-
national meetings. In addition, the bibliographic team
comprised 10 multinational fellows (MA, ASRK, JM, RS, FS,
MS, CvD, IvE, OV and MDW), six mentors (DA, CB, RB, LC,
CJE and RBL) and the scientiﬁc chair (DMvdH). At the ﬁrst
international meeting, clinically relevant questions regarding
gout diagnosis and management were spontaneously proposed,
and 10 were selected via a modiﬁed Delphi voting process by
the panel of 78 expert rheumatologists representing all 14 coun-
tries (table 1). The multinational fellows and supervising
mentors then translated the questions into Population,
Intervention, Comparator, Outcome (PICO) terms, agreed on
the protocols, and undertook SLRs for each clinical question. A
comprehensive search strategy was generated for each question
aided by an experienced librarian (LF) (last date October 2011);
where feasible, search terms were standardised (see online sup-
plementary ﬁgures S1 and S2). Searches were conducted in
Medline, Embase and the Cochrane Central Register of
Controlled Trials (CENTRAL), and hand searches of the refer-
ence list of the selected articles and of abstracts presented at the
2010 and 2011 American College of Rheumatology (ACR) and
European League Against Rheumatism (EULAR) scientiﬁc meet-
ings were performed. Two independent reviewers screened the
titles and abstracts of all citations identiﬁed by the searches,
assessed potentially relevant articles in full text for inclusion
according to predetermined criteria, and performed the data
extraction of the selected studies (see online supplementary
table S1). When discrepancies arose and no consensus could be
reached, a mentor acted as arbiter. Included articles were
restricted to those published in English or in a language in
which at least one member of the bibliographic group was ﬂuent
(Dutch, French, German, Spanish). Standardised tools were
used to assess the risk of bias of included studies (Cochrane Risk
of Bias tool for intervention studies,17 Hayden tool18 for cohort
studies, Newcastle-Ottawa Scale for case–control studies,19 the
Consensus-based stadards for the selection of health measure-
ment instruments (COSMIN) checklist20 for validation of meas-
urement instruments, and the Cochrane Risk of Bias tool for
diagnostic studies21). Where relevant, we considered outcomes
proposed by OMERACT (Outcome Measures in Rheumatology
Clinical Trials) to be used in the evaluation of interventions for
acute and chronic gout.22 We planned to pool relevant data
from included studies provided that they were sufﬁciently
homogeneous. This was predeﬁned in each SLR protocol.
Details and results of the SLR for each question will be pub-
lished separately, but a summary of the supporting evidence is
presented under each recommendation in the Results section.
After presentation of the SLR results, each of the 12 national
scientiﬁc committees produced recommendations leading from
the 10 clinical questions. At the ﬁnal international meeting,
members of each of the scientiﬁc committees merged the
national recommendations into 10 ﬁnal multinational recom-
mendations through a process of discussion and a modiﬁed
Delphi vote with an electronic voting system (up to three
rounds with prespeciﬁed cut-off points). The participating rheu-
matologists quantiﬁed their agreement with each recommenda-
tion on a 1–10 scale (fully disagree to fully agree), and the
potential impact of each recommendation on their clinical prac-
tice on a multiple choice question (recommendation will change
my practice/is in accordance with my practice/I don’t want to
apply this recommendation). The level of evidence for each rec-
ommendation was appraised and graded in accordance with the
Oxford Centre for Evidence-based Medicine Levels of
Evidence.23 Where there was ambiguity regarding the appropri-
ate grade or level of evidence, a lower grade or level was chosen.
RESULTS
The 10 ﬁnal multinational recommendations are listed in table 2
with the levels of evidence and grades of recommendation; a
summary of the supporting evidence and the expert opinion on
each recommendation are presented below. The level of agreement
by the rheumatologists with the recommendations ranged from
8.1 to 9.2 (mean 8.7) on a 1–10 point scale where 10 represents
full agreement. For every recommendation, the proportion of
rheumatologists voting 7 or more was over 80%. Many rheuma-
tologists felt that the recommendations were in full accordance
with their current practice (table 3). However, for two recommen-
dations for which there was a lower accordance with current prac-
tice (comorbidity screen of renal function and cardiovascular risk
factors, and achieve tight control of SUA in patients with tophi),
there was a higher willingness to change current practice.
Table 1 Ten clinical questions of the Evidence, Expertise, Exchange (3e) Initiative
1 In which circumstances can a diagnosis of gout be made on clinical grounds with or without laboratory tests or imaging and when is the identification of
crystals necessary?
2 In patients with hyperuricaemia and/or the diagnosis of gout, should we screen routinely for comorbidities and CV risk factors?
3 What is the role of glucocorticoids, colchicine, NSAIDs, anti-IL1 and paracetamol in the management of acute gout?
4 Which lifestyle changes (such as diet, alcohol intake, weight loss, smoking and/or exercise) are efficacious in the treatment/prevention of gout?
5 What is the efficacy, cost-efficacy and safety for ULT (allopurinol, but also febuxostat, peg-uricase, benzbromarone and probenecid) in the treatment of
gout? Which sequence of ULT or combinations of should be recommended?
6 When introducing ULT, what is the best treatment to prevent an acute attack and for how long should it be continued? When is the optimum time to
start ULT after an acute attack of gout?
7 How do common comorbidities (such as metabolic syndrome, CV, GI and renal disease) influence the choice of gout-specific drugs (such as colchicine,
allopurinol and other ULT) in acute gout flare, chronic gout and in prophylaxis of acute flare?
8 What should be the treatment target and how should patients with gout be followed (with which measures (eg, patient-reported outcomes, clinical,
biochemical and/or imaging))?
9 How should tophi be managed?
10 Can we prevent gouty arthritis, renal disease and CV events by lowering serum uric acid levels in patients with asymptomatic hyperuricaemia? If yes,
what should be the target levels?
CV, cardiovascular; GI, gastrointestinal; IL, interleukin; NSAID, non-steroidal anti-inflammatory drug; ULT, urate-lowering therapy.
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Recommendation 1: diagnosis
Four studies used MSU crystal identiﬁcation as the reference
standard to evaluate the diagnostic performance of over 60 indi-
vidual clinical, laboratory and imaging ﬁndings.24–27 Most clin-
ical, laboratory and x-ray features—including podagra and
hyperuricaemia—show a low diagnostic utility as stand-alone
ﬁndings with the exception of response to colchicine therapy
and the presence of tophi. Advanced imaging techniques, such
as ultrasound (US) and dual-energy CT, performed better.
Experts showed a strong consensus that identiﬁcation of MSU
crystals—in a joint ﬂuid sample or in a tophi aspirate—is
required for a deﬁnite diagnosis of gout. Since life-long urate-
lowering therapy (ULT) is commonly prescribed after diagnosis,
this procedure should be routinely undertaken. However, as this
might prove difﬁcult in some settings, it was felt that clinical or
imaging ﬁndings could support a diagnosis. The presence of
hyperuricaemia on its own is insufﬁcient to establish a diagnosis
of gout. Response of acute arthritis to colchicine could support
a clinical diagnosis of gout, but was felt unhelpful in differenti-
ating types of crystal arthritis (eg, gout and acute calcium pyro-
phosphate arthritis). Availability, cost and the need for trained
personnel and speciﬁc equipment may limit the use of advanced
imaging techniques in routine clinical practice.
Recommendation 2: comorbidity screening
The focus was on those comorbidities that could be both
screened for and treated. An increased incidence of end-stage
renal disease was found in patients with hyperuricaemia,28 but
gout was not an independent predictor for this disease.29
However, a fourfold increase in mortality due to kidney
disease has been reported in patients with gout compared with
non-gouty patients.30 We identiﬁed evidence that hyperuricae-
mia may increase the risk of developing diabetes or hyperten-
sion31 32; however, no prospective studies were identiﬁed that
investigated the risk of these conditions in people with gout.
The available data showed that hyperuricaemia does not
increase the risk of developing coronary heart disease
(CHD)31–36 or stroke.37–39 On the other hand, there was evi-
dence to suggest that people with gout have an increased risk
of developing CHD40–43 and slightly increased risk of
CHD-related mortality.44
Experts agreed to highlight the need to screen for
renal disease on the basis of the strong evidence of associ-
ation and the implications for gout therapy. Experts
also agreed that hyperuricaemia and gout should be consid-
ered red ﬂags for metabolic syndrome and cardiovascular
diseases.
Table 2 Multinational recommendations on the diagnosis and management of gout
Recommendation
Level of
evidence
Grade of
recommendation
Agreement,
mean (SD)
1 Identification of MSU crystals should be performed for a definite diagnosis of gout; if not possible,
a diagnosis of gout can be supported by classical clinical features* (such as podagra, tophi, rapid
response to colchicine) and/or characteristic imaging findings**
*2b
**2b
*D
**B
8.8 (1.6)
2 In patients with gout and/or hyperuricaemia, renal function should be measured and assessment of
cardiovascular risk factors is recommended
2c C 8.4 (2.1)
3 Acute gout should be treated with low-dose colchicine* (up to 2 mg daily), NSAIDs** and/or
glucocorticoids (intra-articular***, oral**** or intramuscular*****) depending on comorbidities
and risk of adverse effects
*1b−
**1a−
***4
****1a−
*****1a−
*D
**D
***D
****D
*****D
8.9 (1.7)
4 Patients should be advised a healthy lifestyle including reducing excess body weight, performing
regular exercise, smoking cessation, avoiding excess alcohol and sugar sweetened drinks
5 D 8.5 (1.7)
5 Allopurinol should be the first line urate-lowering therapy*; alternatives to consider next include
uricosurics** (eg, benzbromarone, probenecid) or febuxostat***; uricase as monotherapy should only
be considered in patients with severe gout in whom all other forms of therapy have failed or are
contraindicated****. Urate-lowering therapy (except uricase) should be started in a low dose and
escalated to achieve a target serum urate*****
*2b
**2b
***2b
****2b
*****5
*C
**C
***C
****C
*****D
9.1 (1.3)
6 When introducing urate-lowering therapy, patient education on the risk and management of flare is
essential*; prophylaxis should be considered using colchicine (up to 1.2 mg daily)**, or if
contraindicated or not tolerated NSAIDs*** or low dose glucocorticoids**** may be used. The
duration of prophylaxis depends on individual patient factors
*5
**1b
***5
****5
*D
**B
***D
****D
8.1 (2.1)
7 In patients with mild-moderate renal impairment, allopurinol may be used with close monitoring for
adverse events, starting at a low daily dose (50–100 mg) up-titrated to achieve usual target of serum
uric acid*; febuxostat** and benzbromarone*** are alternative drugs that can be used without dose
adjustment
*4
**2b
***4
*D
**B
***D
8.5 (1.7)
8 The treatment target is serum urate below 0.36 mmol/L (6 mg/dL), and the eventual absence of gout
attacks and resolution of tophi*; monitoring should include serum urate level, frequency of gout
attacks and tophi size**
*2b
**1b
*C
**B
9.0 (1.8)
9 Tophi should be treated medically by achieving a sustained reduction in serum uric acid, preferably
below 0.30 mmol/L (5 mg/dL); surgery is only indicated in selected cases (eg, nerve compression,
mechanical impingement or infection)
2b B 9.2 (1.4)
10 Pharmacological treatment of asymptomatic hyperuricaemia is not recommended to prevent gouty
arthritis, renal disease or CV events
2b D 8.6 (2.5)
CV, cardiovascular; MSU, monosodium urate; NSAID, non-steroidal anti-inflammatory drug.
Level of evidence and grade of recommendation were according to the Oxford Centre for Evidence-based Medicine levels of evidence.21 Agreement relates to the entire statement and
was voted on a scale from 1 to 10 (fully disagree to fully agree) by the 70 rheumatologists attending the 3e multinational closing meeting (Brussels, 22–23 June 2012). These attendees
were members of the national scientific committees from the 14 countries involved in 3e.
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Recommendation 3: acute gout
Twenty-six trials were included on treatment of acute gout ﬂares
(21 evaluated non-steroidal anti-inﬂammatory drugs (NSAIDs),45
ﬁve glucocorticoids,46 two colchicine, and one canakinumab47).
The available evidence showed that low-dose colchicine (total
dose 1.8 mg in 24 h) was more effective than placebo48 49 and as
effective as high-dose colchicine (total dose 4.8 mg), but lower
doses of colchicine had a signiﬁcantly better safety proﬁle.49 There
was no high-quality evidence comparing NSAIDs with placebo50
and no NSAID (conventional or selective COX-2 inhibitor) has
proven superior to another.51–67 Three trials concluded that sys-
temic glucocorticoids were as effective as NSAIDs, with a similar
safety proﬁle.68–70 Despite a comprehensive search strategy, no
trials assessing intra-articular glucocorticoids or paracetamol in the
treatment of acute gout ﬂares were identiﬁed.
There was consensus that NSAIDs, colchicine and glucocorti-
coids (given as intra-articular, oral or intramuscular therapy) are
all effective in the treatment of acute gout ﬂares and that there
was insufﬁcient evidence to prioritise them. Individual treatment
decisions should be based on consideration of an individual’s
characteristics and each drug’s safety proﬁle. Paracetamol,
although not recommended as the primary therapy, can be
useful as an adjunct analgesic.
Recommendation 4: lifestyle
There is no evidence to support the idea that intervening in life-
style factors translates into improved outcomes in patients with
gout. Despite a comprehensive search strategy,71 72 only one
study assessing the efﬁcacy of lifestyle interventions in the treat-
ment of chronic gout was identiﬁed.73 The use of skimmed milk
powder enriched with two dairy fractions (glycomacropeptide
and G600 fat extract) did not result in a reduction in frequency
of acute gout ﬂares when compared with standard skimmed
milk or lactose powder.73
Current understanding of the lifestyle factors associated with
gout is largely derived from large, cross-sectional, epidemio-
logical studies. Given the lack of evidence supporting lifestyle
interventions in the treatment of gout per se, experts recom-
mend general healthy lifestyle habits such as would be advisable
for all individuals. Regarding alcohol consumption, experts
agreed that there should be more emphasis on discouraging beer
and spirits over wine intake. Together with general lifestyle
advice, education about the need for compliance with lifelong
ULTwas deemed essential.
Recommendation 5: ULT
Over 40 studies were included in the evaluation of the efﬁcacy,
cost-efﬁcacy and safety of ULT. There is high-quality evidence
that allopurinol,74 febuxostat (40–240 mg daily)74 75 and peglo-
ticase (8 mg intravenously every 2 or 4 weeks)76 are more effect-
ive than placebo in lowering SUA levels in patients with gout.
One study showed that benzbromarone was effective in patients
who failed to reach target uric acid on allopurinol.77 Febuxostat
(80–240 mg daily) was more effective than potentially subopti-
mal doses of allopurinol (300 mg in patients with normal renal
function, 100–200 mg if renal insufﬁciency) in lowering SUA,
with a similar overall safety proﬁle.74 78 79 Step-up therapy with
allopurinol (300–600 mg) or benzbromarone (100–200 mg) are
both effective in lowering SUA levels.80 Pegloticase, although
highly efﬁcacious, is associated with an increase in acute gout
ﬂares, infusion reactions and increased withdrawals due to
adverse events compared with placebo.76 Available evidence for
cost-efﬁcacy was at a high risk of bias81 82 or outdated.83 No
studies addressed the sequence of ULT.
There was a strong consensus that allopurinol constitutes ﬁrst-
line ULT after consideration of its safety, efﬁcacy and cost. Low
starting doses can optimise safety and minimise the risk of acute
ﬂares; doses should be gradually increased until target SUA
levels are achieved (see recommendation 8). Uricosurics—where
available—and low to medium doses of febuxostat (40–120 mg)
are alternatives in the presence of intolerance or non-
responsiveness to allopurinol. Uricase should only be considered
in selected patients without other therapeutic options.
Pegloticase should not be combined with other ULT, as this may
mask the increase in SUA levels warning of an increased risk of
infusion reactions and anaphylaxis.
Recommendation 6: ﬂare prophylaxis
Four studies addressing ﬂare prophylaxis when ULT is initiated
were identiﬁed. In two randomised controlled trials, the use of
colchicine (0.6–1.5 mg daily) for the initial 3–6 months after
the start of ULT resulted in a reduction in the number of
patients who developed acute gout attacks and a reduction in
the severity of these ﬂares compared with placebo.84 85 Despite
an increase in diarrhoea in one study,84 overall adverse effects
and withdrawals were similar between the colchicine and
placebo groups. No evidence on the use of NSAIDs or glucocor-
ticoids as prophylaxis was retrieved.
Experts considered that the need for acute gout ﬂare prophy-
laxis when initiating ULT should be considered on an individual
Table 3 Impact of the recommendations on the practice of rheumatologists of the Evidence, Expertise, Exchange (3e) Initiative
Recommendation (number and topic)
The recommendation
will change my
practice, %
The recommendation
is in full accordance
with my practice, %
I do not want to apply
this recommendation
in my practice, %
1. Diagnosis 7.5 88.7 3.8
2. Comorbidity screening 27.4 60.8 11.8
3. Acute gout 7.5 88.7 3.8
4. Lifestyle 18.5 77.8 3.7
5. Urate-lowering therapy 18.9 79.2 1.9
6. Flare prophylaxis 13.2 69.8 17.0
7. Effect of comorbidities on drug choices 17.0 81.1 1.9
8. Monitoring 16.7 79.6 3.7
9. Tophi 31.5 64.8 3.7
10. Asymptomatic hyperuricaemia 9.8 80.4 9.8
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basis. Optimal duration is currently unclear and should be
decided after assessing factors such as ﬂare frequency, gout dur-
ation and the presence and size of tophi. There was no consen-
sus on when ULT should be started after an acute attack.
However, the majority felt that low initial doses of ULT, with
slow dose increases, is an integral part of ﬂare prevention, sup-
porting the motto ‘start low, go slow’.
Recommendation 7: effect of comorbidities on drug choice
Two studies, of low to moderate quality, showed that gradual
dose escalation of allopurinol in patients with renal impairment
resulted in a higher proportion of patients obtaining target SUA
levels without a parallel increase in serious toxicity,86 87 when
compared with the commonly used and more conservative
dosing guidelines.88 Allopurinol has been compared with other
ULTs in populations with renal impairment of mostly mild or
moderate levels (creatinine clearance >30 mL/min). Both
febuxostat (80 mg/day)74 79 and unadjusted benzbromarone
(100–200 mg/day)89 resulted in a higher proportion of patients
achieving target SUA compared with renal function-adjusted
allopurinol (100–300 mg/day), with a similar safety proﬁle. The
combination of allopurinol and benzbromarone allowed a
reduction in SUA levels except in cases of severe renal
dysfunction.90
Recommendation 8: monitoring
The target for the treatment of any disease is either cure or
control. Both of these goals may be abstract concepts and can be
difﬁcult to measure. Often a surrogate marker associated with the
cure or control is used; in gout, this surrogate marker is
SUA.8 9 11 91–93 The association of SUA with other potential
outcomes22 was systematically reviewed. Six studies linked the
reduction of SUA levels with a decreased rate of acute attacks,94–99
two studies with tophus regression,100 101 and three studies with
crystal disappearance—either through US102 or synovial ﬂuid
microscopy.103 104 The quality of these studies was low to moder-
ate. The most commonly used SUA cut-off point in studies was
0.36 mmol/L (6.0 mg/dL), but there is some evidence that lower
SUA levels could lead to a higher speed of tophi reduction and a
longer time to recurrence of acute attacks after treatment with-
drawal.94 100 Numerous tools have been used for monitoring the
different outcome domains in patients with gout, including bio-
logical markers, clinical features, patient-reported outcomes or
imaging. The physical component of the SF-36 question-
naire,105 106 the Health Assessment Questionnaire,105 107 and
tophus measurement by caliper108 or US109 have shown adequate
clinimetric properties.
Experts considered that monitoring should include at least
SUA levels, the frequency of gouty attacks, and tophi size, but
recommended no speciﬁc tool. They agreed that the target
should be an SUA level below 0.36 mmol/L, but recommended
even lower cut-off points if tophi are present (see recommenda-
tion 9).
Recommendation 9: tophi
After a comprehensive search strategy,110 only four prospective
studies assessing pharmacological agents for patients with
tophaceous gout were identiﬁed: two randomised controlled
trials with pegloticase,76 an open extension study with febuxo-
stat,111 and a case series of patients with tophaceous gout on
different ULTs.100 A sustained reduction in SUA led to tophi
reduction and in some cases resolution, independently of which
ULTwas used. The only evidence for the use of surgery to treat
tophi came from case reports and case series.
Experts agreed that a lower SUA level (0.3 mmol/L) should be
a treatment target for patients with tophaceous gout, as the evi-
dence suggested that lower SUA levels increase the speed of tophi
reduction. Surgery should only be considered in selected cases
(eg, nerve compression, mechanical impingement or infection).
Recommendation 10: asymptomatic hyperuricaemia
Deﬁning asymptomatic hyperuricaemia was controversial; the
agreed deﬁnition excluded patients with a background of arth-
ritis or tophi, but allowed the inclusion of patients with pre-
existing renal or cardiovascular disease. After an extensive
search, only three studies112–114 were retrieved. Patients with
asymptomatic hyperuricaemia and normal renal function112 113
or chronic kidney disease114 at baseline were allocated to
receive allopurinol or no treatment over a 3–12 month period;
no signiﬁcant differences were noted in glomerular ﬁltration
rate, serum creatinine or proteinuria between the two groups.
No studies dealing with prevention of gout or cardiovascular
disease met the inclusion criteria.
Although there was an absence of evidence supporting the
use of ULT for asymptomatic hyperuricaemia, experts agreed
that lifestyle advice on diet, weight loss or exercise would apply
to patients with asymptomatic hyperuricaemia, especially after
considering the increased risks stated in recommendation 2.
DISCUSSION
The 3e Initiative developed 10 recommendations for the diag-
nosis and management of gout. These address questions relevant
to the clinical setting, are informed by the currently available
evidence, and are endorsed by a large international panel of
rheumatologists.
Even though gout is a potentially curable disease, its manage-
ment is far from optimal5 in both primary care and rheumatol-
ogy clinics. The quality of care provided to gout patients needs
to improve. Guidelines that are implemented improve quality of
care,115 and educational outreach has an effect on implementa-
tion14; therefore, we may suppose that multinational evidence-
based recommendations developed in a way in which
education—in both gout and evidence-based medicine116—and
dissemination are ﬁnal aims can contribute towards this goal.
Two sets of recommendations have recently been published:
the ﬁrst by an American group (with a USA perspective)11 and
the second on behalf of the ACR.9 10 The ﬁrst group’s approach
differed from ours, accepting the 2006 EULAR recommenda-
tions7 8 as a basis and reappraising the evidence published in the
past 6 years (2005–2011). The ACR recommendations—
produced following the RAND/University of California at Los
Angeles (UCLA) methodology—centred on the treatment and
prophylaxis of acute gout ﬂares and the appropriate use of ULT
in gout, excluding issues on gout diagnosis or asymptomatic
hyperuricaemia. The recommendations are similar in some areas,
but methodological differences between the 3e Initiative and the
ACR guidelines—including the exclusion of benzbromarone
(unavailable in the USA) and cost and cost-effectiveness apprai-
sals—have given rise to differences in drug therapy hierarchies.
The 3e recommendations have been developed through an
established process with a number of strengths. First, the formal
voting process of a broad international panel representing
several continents resulted in the development of 10 relevant
clinical questions. Second, the available evidence was appraised
and summarised following a rigorous approach, which was then
combined with the experience of numerous rheumatologists.
Last, the high level of agreement with the ﬁnal recommenda-
tions and the multinational participation increases their utility
332 Sivera F, et al. Ann Rheum Dis 2014;73:328–335. doi:10.1136/annrheumdis-2013-203325
Recommendation
and will hopefully facilitate their dissemination and implementa-
tion worldwide. Most participating rheumatologists either
follow the recommendations or are willing to change their prac-
tice according to them, suggesting a solid potential impact of
this set of recommendations.
A number of limitations of these recommendations must,
however, be taken into account. Other specialties (eg, nephrol-
ogy, primary care), health professionals and patients have not
participated in the development of these recommendations. It is
therefore unclear how applicable or relevant they are in non-
rheumatological settings. Also, many recommendations are
complex, including several statements with different degrees of
evidence. However, experts voted on their global agreement
with the entire recommendation. Finally, variability in agree-
ment of some recommendations suggests a certain degree of dis-
persion; however, it must be noted that the proportion of
attending rheumatologists voting 7 or over for each recommen-
dation was over 80%, suggesting a signiﬁcant degree of support
for these recommendations.
In summary, 10 multinational recommendations for the diag-
nosis and management of patients with gout in daily clinical
practice have been developed, integrating SLR and expert
opinion, with the aim of improving patient care.
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